<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2505233731
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TOBREX OPTH.OINT. 0.3%
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOBRAMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye ointment
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="S.A. Alcon Couvreur N.V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            S.A. Alcon Couvreur N.V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01AA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>TOBREX is an antibiotic for the eye (contains tobramycin).</li><li>TOBREX is indicated for the topical treatment of infections of the eye and the tissues around the eye, in adults and children aged 1 year and older, caused by bacteria sensitive to tobramycin. These are in particular bacteria that are resistant to most other antibiotics, especially <em>Pseudomonas aeruginosa</em>.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. </strong><strong>Do not use TOBREX</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to tobramycin or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to aminoglycosides, a group of antibiotics including TOBREX.</p><p>&nbsp;</p><p><strong>b. </strong><strong>Take special care with TOBREX</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only use TOBREX in your <strong>eyes</strong>. It should not be injected or swallowed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If signs of allergic reactions occur</strong>, discontinue the treatment and consult your doctor again. Allergic reactions may vary from localized itching or skin redness to severe allergic reactions (anaphylactic reaction) or serious skin reactions. These allergic reactions may also occur with other topical or systemic antibiotic of the same family (aminoglycosides).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>using any other antibiotic medicines</strong> by mouth or by injection <strong>or any other medication</strong> (by mouth, injection or topical), tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe side effects including nervous system, hearing and kidney problems have been observed in patients taking oral tobramycin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or if you have ever had conditions such as myasthenia or Parkinson&rsquo;s disease, ask your doctor for advice. Antibiotics of this kind may worsen muscle weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your symptoms get worse or suddenly return, please consult your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you use TOBREX <strong>for a long period of time</strong> you may become more susceptible to eye infections. If superinfection occurs please contact your doctor so that appropriate therapy can be initiated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you wear contact lenses:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wearing contact lenses (hard or soft) is not recommended during treatment of an eye infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you continue to wear contact lenses nonetheless, remove them before using TOBREX and wait 15 minutes before putting your lenses back in.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using other medicines, please also read the section &ldquo;Other medicines and TOBREX&rdquo;.</p><p>&nbsp;</p><p>Consult your doctor if one of the above warnings is applicable to you or has been in the past. Talk to your doctor or pharmacist before using TOBREX.</p><p>&nbsp;</p><p><strong>c.&nbsp; </strong><strong>Children</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TOBREX may be used in children 1 year of age and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give TOBREX to children younger than 1 year old because the safety and efficacy in this population have not been established.</p><p>&nbsp;</p><p><strong>d. </strong><strong>&nbsp;Using other medicines and TOBREX</strong></p><p>If you are using other eye preparations, wait at least 5 minutes between each application. Administer ointments last.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.</p><p>&nbsp;</p><p><strong>e.&nbsp; </strong><strong>Using TOBREX with food and drink</strong></p><p>No influence.</p><p>&nbsp;</p><p><strong>f.&nbsp; </strong><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>TOBREX is not recommended during pregnancy. TOBREX should be used during pregnancy only if clearly needed.</p><p>Your doctor will decide whether you may use TOBREX during breast-feeding or have to stop breast-feeding.</p><p>&nbsp;</p><p><strong>g. </strong><strong>Driving and using machines</strong></p><p>If your vision becomes temporarily blurred after applying TOBREX, do not drive or operate machines until your vision has become clear again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</li><li>Your doctor will tell you how long you should use TOBREX. <strong>Do not stop the treatment early, </strong>even if your symptoms improve.<p><strong>The recommended dose </strong>in adults and children 1 year of age and older:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in mild diseases:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a small amount of ointment (a &lsquo;ribbon&rsquo;) in the affected eye(s) 2 to 3 times per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in severe cases:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a small amount of ointment in the affected eye(s) every 3 to 4 hours, until improvement.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upon improvement, gradually reduce the number of applications per day. Do not stop the treatment abruptly.</p><p>&nbsp;</p><p>The length of the treatment is dependent on the origin of the infection and may vary from a couple of days up to several weeks.</p><p>&nbsp;</p><p><strong>Only</strong> use TOBREX in your eye(s).</p><p><strong>Instructions for use:</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
 margin-left:170.9pt;margin-top:5.7pt;width:73.5pt;height:58.5pt;z-index:251656704'
 fillcolor="window">
 <v:imagedata src="file:///C:/Users/khalian2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.jpg"
  o:title="geopend oog met tube"/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img src="data:image/png;base64,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" alt="" width="972" height="235" vspace="0" hspace="0" border="0" style="width:972px;height:235px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Wash your hands</strong> before using TOBREX.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sit down in front of a mirror, so that you can see what you are doing.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist off the tube cap.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Make sure the tube tip touches nothing else</strong>, as this may contaminate the contents.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tilt your head back.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull down the lower eyelid of the affected eye with a finger until there is a &quot;pocket&quot; between the eyelid and the eye (Picture 1). The ribbon of ointment must go here.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bring the tube tip close to your eye. Use the mirror if it helps.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t touch your eye or eyelid, surrounding areas, or other surfaces with the tube tip.</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently squeeze the tube to expel the ribbon of ointment into the &ldquo;pocket&rdquo; (Picture 2).</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close your eye for a few seconds after putting the ointment into your eye (Picture 3).</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps e through j for your other eye, if necessary. Close the tube cap firmly.</p><p>&nbsp;</p><p><strong>If you are using eye drops or other eye ointment medicines, </strong>leave at least 5 minutes between each medicine. Eye ointments should be administered last.<strong> </strong></p><p>&nbsp;</p><p><strong>If you use more TOBREX than you should</strong></p><p>If you have applied more TOBREX into your eye than necessary, you can rinse it out of your eye with lukewarm water. However, no undesirable effects are to be expected. Do not put in any more ointment until it is time for your next dose.</p><p><strong>&nbsp;</strong></p><p>If you have used more TOBREX than you should or if you have accidentally <strong>swallowed</strong> TOBREX, immediately seek advice from your doctor, pharmacist .</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to use TOBREX</strong></p><p>Administer the forgotten dose as soon as possible. <strong>However, do not use a double dose to make up for the missed dose:</strong> if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.</p><p>&nbsp;</p><p><strong>If you stop using TOBREX</strong></p><p>Do not stop using TOBREX before the end of the stated treatment period. If the treatment is stopped prematurely, there is a possibility that the infection will re-occur.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, TOBREX can cause side effects, although not everybody gets them.</p><p>The side effects have been grouped according to their frequency of occurrence: &ldquo;<strong>very</strong> <strong>common</strong>&rdquo;: occurs in more than 1 in 10 patients, &ldquo;<strong>common</strong>&rdquo;: between 1 in 10 and 1 in 100 patients, &ldquo;<strong>uncommon</strong>&rdquo;: between 1 in 100 and 1 in 1000 patients, &ldquo;<strong>rare</strong>&rdquo;: between 1 in 1000 and 1 in 10000 patients, &ldquo;<strong>very</strong> <strong>rare</strong>&rdquo;: occurs in less than 1 in 10000 patients and &ldquo;<strong>not</strong> <strong>known</strong>&rdquo;: cannot be estimated from the available data.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Common:</strong> redness of the eye - eye discomfort.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon:</strong> eye surface inflammation - corneal damage - visual impairment - eyelid redness - eye discharge - eyelid abnormality - eye and eyelid swelling - eye irritation - blurred vision - eyelid redness - eye pain - dry eye - itchy eye - increased tear production.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known: </strong>eye allergy - eyelid itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Reactions in other parts of your body:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon: </strong>allergy (hypersensitivity) - headache - hives - skin inflammation - decreased growth or number of eyelashes - loss of pigmentation of the skin - itching - dry skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known:</strong> skin redness - severe allergic reaction - serious skin reactions (Stevens-Johnson syndrome and erythema multiforme).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 25&deg;C. Do not refrigerate.</p><p><strong>Do not use TOBREX longer than 4 weeks after first opening.</strong></p><p>Do not use this medicine after the expiry date which is stated on the carton and the tube after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is tobramycin (3 mg/g).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are anhydrous chlorobutanol, liquid paraffin and vaseline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TOBREX eye ointment is supplied in a 3.5 g aluminium tube with a screw cap.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised by Belgian health authorities in 09/2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">عقار توبريكس عبارة عن مضاد حيوي للعين (يحتوي على توبراميسين).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يُستخدَم عقار توبريكس للعلاج الموضعي لعدوى العين والأنسجة حول العين، التي تُسببها البكتيريا ذات الحساسية تجاه توبراميسين في البالغين والأطفال من عمر عام واحد فأكثر. على وجه الخصوص، هذه البكتيريا مقاومة لمعظم المضادات الحيوية الأخرى، وخاصة <em>الزائفة الزنجارية</em>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">&nbsp;&nbsp;&nbsp;&nbsp; &zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تستخدم عقار توبريكس في الحالات الآتية</strong><strong>:</strong></p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه توبراميسين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه الأمينُوجْليكُوزيدات، وهي مجموعة من المضادات الحيوية بما في ذلك عقار توبريكس.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;&nbsp; &zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>توخ حذرًا خاصًّا مع عقار توبريكس</strong></p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عقار توبريكس إِلَّا داخل <strong>عينيك</strong>. يجب أَلَّا يتم حقنه أو ابتلاعه.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا ظهرت علامات لتفاعلات حساسية </strong>فقم بوقف العلاج واستشر طبيبك مرة أخرى. قد تتباين تفاعلات الحساسية من الحكة الموضعية أو احمرار الجلد إلى تفاعلات حساسية شديدة (التَّفاعل التَّأَقِيّ) أو تفاعلات جلدية خطيرة. قد تحدث أيضًا تفاعلات الحساسية هذه مع المضادات الحيوية الموضعية أو الجهازية الأخرى من نفس المجموعة (الأمينوجليكوزيدات).</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تستخدم أية مضادات حيوية أخرى</strong> عن طريق الفم أو عن طريق الحقن<strong> أو تستخدم أية أدوية أخرى </strong>(عن طريق الفم أو الحقن أو موضعية)، أخبر طبيبك بذلك.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لُوحظ حدوث آثار جانبية شديدة تتضمن مشاكل بالجهاز العصبي، وحاسة السمع والكُلى في المرضى ممن يتناولون توبراميسين عن طريق الفم.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُرجى استشارة طبيبك إذا كنت مصابًا أو قد أصبت من قبل بحالات مثل الوهن العضلي أو مرض الشلل الرعَّاش (مرض باركنسون). فقد يُؤدي ذلك النوع من المضادات الحيوية إلى تفاقم ضعف العضلات.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تفاقمت الأعراض لديك أو عادت فجأة، فيرجى استشارة طبيبك.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استخدمت عقار توبريكس لفترة طويلة من الوقت، فقد تصبح أكثر عرضة للإصابة بعدوى العين. إذا حدثت إصابة بعدوى إضافية، يُرجى الاتصال بطبيبك بحيث يمكن بدء العلاج الملائم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت ترتدي عدسات لاصقة</strong><strong>:</strong></p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُنصح بارتداء العدسات اللاصقة (الصلبة أو اللينة) أثناء علاج عدوى العين.</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا واصلت ارتداء العدسات اللاصقة على الرَّغم من ذلك، فقم بإزالتها قبل استخدام عقار توبريكس وانتظر لمدة 15 دقيقة قبل ارتداء عدساتك مرة أخرى.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية أخرى، يُرجى أيضًا قراءة قسم: &quot;استخدام أدوية أخرى مع عقار توبريكس&quot;.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">استشر طبيبك إذا كان ينطبق عليك، أو قد انطبق عليك في الماضي أي من التحذيرات أعلاه. تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام عقار توبريكس.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;&nbsp; &zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأطفال</strong></p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام عقار توبريكس في الأطفال من عمر عام واحد فأكثر.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تعطِ عقار توبريكس للأطفال الذين تقل أعمارهم عن عام واحد؛ لأنَّه لم يتم التَّحقق من أمان العقار وفعاليته في هذه الفئة العمرية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;&nbsp;&nbsp; &zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;استخدام أدوية أخرى مع عقار توبريكس</strong></p><p style="direction: rtl;">إذا كنت تستخدم مستحضرات أخرى للعين، فعليك الانتظار لمدة 5 دقائق على الأقل بين كل مستحضر والآخر. تكون المراهم آخر ما يتم استخدامه.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;&nbsp;&nbsp; &zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استخدام عقار توبريكس مع الأغذية والمشروبات</strong></p><p style="direction: rtl;">ليس له تأثير.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;&nbsp;&nbsp; &zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p style="direction: rtl;">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدَّواء.</p><p style="direction: rtl;">لا يُوصى باستخدام عقار توبريكس خلال فترة الحمل. يجب عدم استخدام عقار توبريكس أثناء الحَمْل إِلَّا إذا كانت هناك ضرورة واضحة لذلك.</p><p style="direction: rtl;">سيقرر طبيبكِ ما إذا كان بإمكانكِ استخدام عقار توبريكس أثناء الرضاعة الطبيعيَّة أو يجب عليكِ إيقاف الرضاعة الطبيعيَّة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;&nbsp;&nbsp; &zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القيادة واستخدام الآلات</strong></p><p style="direction: rtl;">إذا أصبحت الرؤية لديك غير واضحة بشكل مؤقت بعد استخدام عقار توبريكس، فلا تقم بممارسة القيادة أو تشغيل الآلات حتى تتضح الرؤية لديك مرة أخرى.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">استخدم هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">سيخبرك طبيبك بالمدة التي يجب عليك استخدام عقار توبريكس خلالها. <strong>لا توقف العلاج مبكرًا،</strong> حتى إذا تحسنت الأعراض لديك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الجرعة الموصى بها </strong>في البالغين والأطفال من عمر عام واحد فأكثر:</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الأمراض البسيطة:</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية صغيرة من المرهم (شريط) في العين (الأعين) المصابة مرتين إلى ثلاث مرات في اليوم.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الحالات الشَّديدة:</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية صغيرة من المرهم في العين (الأعين) المصابة كل 3 إلى 4 ساعات، حتى يتم التَّحسن.</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند التَّحسن، قم تدريجيًّا بخفض عدد مرات الاستخدام في اليوم.&nbsp; لا توقف العلاج بشكل مفاجئ.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يعتمد طول فترة العلاج على أصل العدوى وقد تتباين من يومين حتى عدة أسابيع.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تستخدم عقار توبريكس إِلَّا داخل عينك/ <strong>عينيك</strong>.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><em>تعليمات الاستخدام:</em></p><p style="direction: rtl;"><em><img src="data:image/png;base64,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" alt="" width="972" height="235" vspace="0" hspace="0" border="0" style="width:972px;height:235px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></em></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اغسل يديك</strong> قبل استخدام عقار توبريكس.</p><p style="direction: rtl;">&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجلس أمام مرآة حتى تتمكن من رؤية ما تقوم بفعله.</p><p style="direction: rtl;">&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدر غطاء الأنبوب لنزعه.</p><p style="direction: rtl;">&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تأكد من عدم ملامسة طرف الأنبوب لأي شيء آخر؛</strong> إذ قد يلوث هذا المحتويات.</p><p style="direction: rtl;">&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإمالة رأسك إلى الخلف.</p><p style="direction: rtl;">&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب الجفن السفلي للعين المصابة بإصبعك حتى يكون هناك &quot;جيب&quot; بين الجفن والعين (الصورة 1). يجب وضع شريط المرهم هنا.</p><p style="direction: rtl;">&zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجلب طرف الأنبوب بالقرب من عينك. استخدم المرآة إذا كان ذلك سيُساعدك.</p><p style="direction: rtl;">&zwnj;ح.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس عينك أو جفنك أو المناطق المحيطة بهما أو الأسطح الأخرى بطرف الأنبوب.</p><p style="direction: rtl;">&zwnj;ط.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط برفق على الأنبوب لإخراج المرهم منه إلى داخل &quot;الجيب&quot; (صورة 2).</p><p style="direction: rtl;">&zwnj;ي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أغلق عينك لبضع ثوان بعد وضع المرهم بداخل عينك (صورة 3).</p><p style="direction: rtl;">&zwnj;ك.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرر الخطوات من &quot;هـ&quot; إلى &quot;ي&quot; لعينك الأخرى، إذا اقتضى الأمر. أغلق غطاء الأنبوب بإحكام.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كنت تستخدم قطرات للعين أو مراهم أخرى للعين، فانتظر 5 دقائق على الأقل بين كل دواء والآخر. يجب أن تكون مراهم العين آخر ما يتم استخدامه.<strong> </strong></p><p style="direction: rtl;"><strong>إذا استخدمت كمية أكثر مما يجب من عقار توبريكس</strong></p><p style="direction: rtl;">إذا قمت بوضع كمية أكثر من الضَّروري من عقار توبريكس بداخل عينك، يمكنك شطفها من عينك بماء فاتر.ومع ذلك، لا يتوقع حدوث آثار جانبية. لا تضع المزيد من المرهم حتى حلول موعد جرعتك التَّالية.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">إذا استخدمت كمية أكثر مما يجب من عقار توبريكس أو إذا <strong>ابتلعت</strong> عقار توبريكس بطريق الخطأ، فاطلب المشورة فورًا من طبيبك أو الصيدلي الخاص بك.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>إذا نسيت استخدام عقار توبريكس </strong></p><p style="direction: rtl;">استخدم الجرعة التي أغفلتها في أسرع وقت ممكن. <strong>ومع ذلك، لا تستخدم جرعة مضاعفة لتعويض الجرعة التي أغفلتها</strong><strong>:</strong> إذا كان قد اقترب موعد الجرعة التَّالية، فتجاوز الجرعة التي أغفلتها واستمر في تلقي الجرعات وفقًا لجدولك المعتاد.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا توقفت عن استخدام عقار توبريكس</strong></p><p style="direction: rtl;">لا تتوقف عن استخدام عقار توبريكس قبل نهاية فترة العلاج المحددة. عند إيقاف العلاج مبكرًا، فهناك احتمالية بتكرار حدوث العدوى مرة أخرى.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">مثله مثل كافة الأدوية، قد يُسبب عقار توبريكس آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p style="direction: rtl;">تم تصنيف الآثار الجانبية وفقًا لمعدل تكرار حدوثها: <strong>&quot;</strong><strong>شائعة جدًّا</strong><strong>&quot;:</strong> تحدث في أكثر من مريض واحد من بين كل 10 مرضى، <strong>&quot;</strong><strong>شائعة</strong><strong>&quot;:</strong> بين مريض واحد من بين كل 10 مرضى ومريض واحد من بين كل 100 مريض، <strong>&quot;</strong><strong>غير شائعة</strong><strong>&quot;:</strong> بين مريض واحد من بين كل 100 مريض ومريض واحد من بين كل 1,000 مريض، <strong>&quot;</strong><strong>نادرة</strong><strong>&quot;:</strong> بين مريض واحد من بين كل 1,000 مريض ومريض واحد من بين كل 10,000 مريض، <strong>&quot;</strong><strong>نادرة جدًّا</strong><strong>&quot;:</strong> تحدَّث في أقل من مريض واحد من بين كل 10,000 مريض و<strong>&quot;</strong><strong>غير معروفة</strong><strong>&quot;:</strong> لا يمكن تقديرها من واقع البيانات المتاحة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضطرابات العين</strong><strong>:</strong></p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شائعة</strong><strong>:</strong> احمرار العين -شعور بانزعاج في العين.</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة</strong><strong>:</strong> التهاب سطح العين، تلف القرنية، قصور البصر، احمرار الجفن،&nbsp; إفرازات من العين، اضطراب الجفن، تورُّم العين والجفن، تهيج العين، عدم وضوح الرؤية، احمرار الجفن، ألم بالعين، جفاف العين، حكة بالعين، زيادة إفراز الدموع.</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروفة</strong><strong>: </strong>حساسية بالعين، حكة بالجفن.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في مناطق أخرى من جسمك:</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة</strong><strong>: </strong>الحساسية (فرط الحساسية)، صداع، شرى (أرتكاريا)، التهاب الجلد، انخفاض نمو الأهداب (الرموش) أو نقص عددها، فقدان تصبُّغ الجلد، حكة، جفاف الجلد.</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروفة</strong><strong>:</strong> احمرار الجلد -تفاعلات حساسية شديدة، تفاعلات جلدية خطيرة (متلازمة ستيفنز جونسون واحمرار متعدد الأشكال).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</li><li>لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية. لا تعرضه للتبريد.</li><li><strong>لا تستخدم عقار توبريكس لفترة أطول من أربعة أسابيع بعد فتحه لأول مرة</strong><strong>.</strong></li><li>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والأنبوب بعد كلمة &laquo;EXP&raquo;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</li><li>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي توبراميسين (3 مجم/ جرام).</p><p style="direction: rtl;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوروبوتانول غير المائي، البارافين السائل والفازلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            يتوفر عقار توبريكس مرهم للعين في أنبوب ألمونيوم 3.5 جم مزود بغطاء لولبي.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p style="direction: rtl;">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تمت آخر مراجعة لهذه النَّشرة من قِبل السلطات الصحية البلجيكية في: 09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TOBREX 3 mg/g eye ointment
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TOBREX eye ointment:
1 g eye ointment contains 3 mg tobramycin.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Eye ointment
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBREX is indicated for the treatment of external infections of the eye and its adnexa, caused by bacteria sensitive to tobramycin, in particular those resistant to most other antibiotics, especially Pseudomonas aeruginosa, in adults and children aged 1 year and older (see section 5.1).</p><p>As with other antibiotics, appropriate monitoring of bacterial response to treatment should be performed.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In mild disease: 1 or 2 drops in the eye(s) every 4 hours, or a small amount of ointment 2 to 3 times per day.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In more severe infections: 2 drops in the eye(s) hourly or a small amount of ointment every 3 to 4 hours until improvement, following which treatment should be reduced prior to discontinuation.</p><p>&nbsp;</p><p>The length of the treatment is dependent on the origin of the infection and may vary from a couple of days up to some weeks.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>TOBREX eye drops and eye ointment may be used in children 1 year of age and older at the same dose as in adults. Currently available data is described in section 5.1. The safety and efficacy of TOBREX eye drops and eye ointment in children younger than 1 year of age have not been established. No data are available.</p><p><em><u>&nbsp;</u></em></p><p><em>Older people</em></p><p>No overall clinical differences in safety or efficacy have been observed between the elderly and other adult populations.</p><p><em>&nbsp;</em></p><p><em>Use in hepatic and renal impairment</em></p><p>TOBREX eye drops and eye ointment have not been studied in these patient populations. However, due to low systemic absorption of tobramycin after topical administration of this product, dose adjustment is not necessary.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For ocular use.</p><p>&nbsp;</p><p>TOBREX eye drops: after cap is removed from eye drops bottle, if tamper evident snap collar is loose, remove before using product.</p><p>&nbsp;</p><p>To prevent contamination of the dropper tip/ tube tip and solution/ointment, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip/tube tip. Keep the bottle/tube tightly closed when not in use.</p><p>&nbsp;</p><p>In case of concomitant therapy with other topical ocular medicines, an interval of at least 5&nbsp; minutes should be allowed between successive applications. Eye ointments should be administered last.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Hypersensitivity to aminoglycosides.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>For topical ophthalmic use only. Not for injection or ingestion.</li><li>Cross-hypersensitivity with other aminoglycosides can occur. The possibility that patients who become sensitized to topical ocular tobramycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.</li><li>Sensitivity to topically administered aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticarial, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. &nbsp;If hypersensitivity develops during use of this medicine, treatment should be discontinued and other medications used (see section 4.8)</li><li>Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Caution is advised when TOBREX is used concomitantly with systemic aminoglycosides and care should be taken to monitor total serum concentrations (see section 4.8).</li><li>Caution should be exercised when prescribing TOBREX to patients with known or suspected neuromuscular disorders such as myasthenia gravis or Parkinson&rsquo;s disease. Aminoglycosides may aggravate muscle weakness because of their potential effect on neuromuscular function.</li><li>As with other antibiotic preparations, prolonged use of TOBREX may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.</li><li>Contact lens wear is not recommended during treatment of an ocular infection. Therefore, patients should be advised not to wear contact lenses during treatment with the product.</li><li>This medicine contains 0,1 mg benzalkonium chloride in each ml. Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Patients should remove contact lenses before using this medicine and put them back 15 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if the patient has dry eyes or a disorder of the cornea (the clear layer at the front of the eye).</li></ul><ul><li>After application of TOBREX eye drops following measures are useful to reduce systemic absorption:</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; keep the eyelid closed for 2 minutes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; close the lachrymal duct with the finger for 2 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. No clinically relevant interactions have been described with topical ocular dosing of TOBREX.</p><p>&nbsp;</p><p>Concomitant and/or sequential use of an aminoglycoside (tobramycin) and other systemic, oral, or topical drugs that have neurotoxic, ototoxic, or nephrotoxic effects may result in additive toxicity and should be avoided, whenever possible.</p><p>&nbsp;</p><p>Topical corticosteroids, when used in combination with tobramycin, may mask the clinical signs of bacterial, fungal, or viral infections and may suppress hypersensitivity reactions.</p><p>&nbsp;</p><p>If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is no or limited data from the use of topical ocular tobramycin in pregnant women.</p><p>Human studies have not shown an association between the administration of tobramycin and malformations. Tobramycin does cross the placenta into the fetus after intravenous dosing in pregnant women. Tobramycin is not expected to cause ototoxicity from in utero exposure.</p><p>Studies in animals have shown reproductive toxicity after systemic exposure and at dosages considered sufficiently in excess of the maximal human dose in therapeutic use derived from tobramycin eye drops so as to have limited clinical relevance (see Section 5.3).</p><p>Although systemic exposure to tobramycin from the topical route of administration is expected to be negligible, as a precautionary measure, it is preferable to avoid the use of Tobramycin during pregnancy. TOBREX should be used during pregnancy only if clearly needed</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>Minimal exposure of tobramycin in breast milk in lactating women was found after intravenous or intramuscular administration of up to 150 mg TID of tobramycin. Even though there is no specific systemic exposure data for tobramycin after ophthalmic administration, given the much smaller doses of these drugs administered topically to the eye compared to the systemic doses noted above with minimal transfer into breast milk, no effects on the breast fed newborn/infant are anticipated. Topical ocular tobramycin can be used during breast-feeding if the benefit to the mother is considered to outweigh the risk to the breast fed newborn/infant.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>Studies have not been performed to evaluate the effect of tobramycin administration on human or animal fertility. (see Section 5.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBREX eye drops and ointment have no or negligible influence on the ability to drive and use machines. As with any other eye preparation, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at application, the patient must wait until the vision clears before driving or using machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In clinical trials, the most frequently reported adverse reactions were ocular hyperaemia and ocular discomfort, occurring in approximately 1.4% and 1.2% of patients.</p><p>&nbsp;</p><p>The following adverse reactions are classified according to the following convention:<br />very common (&ge; 1/10), common (&ge; 1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100),<br />rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data).&nbsp; Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp; The adverse reactions were obtained from clinical trials and postmarketing spontaneous reports. The following adverse reactions were observed following ophthalmic use of TOBREX:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Classification</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:bottom"><p><em>Uncommon: </em>hypersensitivity.</p><p><em>Not known:</em> anaphylactic reaction.</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:bottom"><p><em>Uncommon: </em>headache.</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:bottom"><p><em>Common:</em> ocular discomfort, ocular hyperaemia.</p><p><em>Uncommon:</em> keratitis, corneal abrasion, visual impairment, vision blurred, erythema of eyelid, eyelid oedema, eye discharge, eyelid disorder, conjunctival oedema, eye irritation, eye pain, dry eye, eye pruritus, lacrimation increased.</p><p><em>Not known:</em> eye allergy, eyelids pruritus.</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:bottom"><p><em>Uncommon: </em>urticaria, dermatitis, madarosis, leukoderma, pruritus, dry skin<em>.</em></p><p><em>Not known: </em>rash, erythema, Stevens Johnson&rsquo;s syndrome, erythema multiforme.</p></td></tr></tbody></table><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>Description of selected adverse events</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to topically administered aminoglycosides may occur in some patients (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic tobramycin therapy (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TOBREX may be used in children 1 year of age and older at the same dose as in adults. Currently available data is described in section 5.1. The safety and efficacy in children younger than 1 year of age have not been established, and no data are available (see section 4.2).&nbsp;</p><p>&nbsp;</p><p><u>Pediatric population:</u></p><p>The frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the characteristics of this preparation, no toxic systemic effects are to be expected with the ophthalmic use of this product, with an ocular overdose of this product, or in the event of accidental ingestion of the contents of one bottle/tube.</p><p>&nbsp;</p><p>A topical overdose of TOBREX may be flushed from the eye(s) with lukewarm water.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ophthalmologicals; anti-infectives, ATC code: S01A A12</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Tobramycin is a potent, broad-spectrum, fast-working bactericidal aminoglycoside antibiotic. It exerts its primary effect on bacterial cells by inhibiting polypeptide assembly and synthesis on the ribosome.</p><p>&nbsp;</p><p><u>Mechanism of resistance</u></p><p>Resistance to tobramycin occurs by several different mechanisms including (1) alterations of the ribosomal subunit within the bacterial cell; (2) interference with the transport of tobramycin into the cell, and (3) inactivation of tobramycin by an array of adenylylating, phosphorylating, and acetylating enzymes. Genetic information for production of inactivating enzymes may be carried on the bacterial chromosome or on plasmids. Cross resistance to other aminoglycosides may occur.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>The breakpoints and the <em>in vitro</em> spectrum as mentioned below are based on systemic use. These breakpoints might not be applicable on topical ocular use of the medicinal product as higher concentrations are obtained locally and the local physical/chemical circumstances can influence the activity of the product on the site of administration.&nbsp; In accordance with EUCAST, the following breakpoints are defined for tobramycin:</p><p>&nbsp;</p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enterobacteriaceae&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>S &le; 2 mg/l, R &gt; 4 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pseudomonas spp.</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 4 mg/l, R &gt; 4 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Acinetobacter spp.</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 4 mg/l, R &gt; 4 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus spp.</em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 1 mg/l, R &gt; 1 mg/l</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not species-related&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S &le; 2 mg/l, R &gt; 4 mg/l</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>The information listed below gives only an approximate guidance on probabilities whether microorganisms will be susceptible to tobramycin in<sup> </sup>TOBREX. Bacterial species that have been recovered from external ocular infections of the eye such as observed in conjunctivitis are presented here.</p><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable; particularly when treating severe infections as necessary expert advice should be sought when the local prevalence of resistance is such that the utility of tobramycin in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacillus megaterium</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacillus pumilus</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium accolens</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium bovis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium macginleyi</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Corynebacterium pseudodiphtheriticum</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Kocuria kristinae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em> (methicillin susceptible &ndash; MSSA)</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus epidermidis</em> (coagulase-positive and &ndash;negative)</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus haemolyticus</em> (methicillin susceptible &ndash; MSSH)</p><p><em>Streptococci</em> (inlcuding some of the group A beta-hemolytic species, some nonhemo-lytic species, and<u> </u>some Streptococcus pneumonia)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter calcoaceticus</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter aerogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter junii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter ursingii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Citrobacter koseri</em></p></td></tr><tr><td style="vertical-align:top"><p><em>H. aegyptius</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella oxytoca</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Morganella morganii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella oslonensis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella lacunata</em></p></td></tr><tr><td style="vertical-align:top"><p>Some<em> Neisseria </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus mirabilis</em></p></td></tr><tr><td style="vertical-align:top"><p>Most <em>Proteus vulgaris</em> strains</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Serratia liquifaciens</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><u>Anti-bacterial activity against other relevant pathogens</u></strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MIGHT BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter baumanii</em><em> </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacillus cereus</em><em> </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacillus thuringiensis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Kocuria rhizophila</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus haemolyticus </em>(methicillineresistent - MRSH)</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus, </em>other coagulase-negative spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Serratia marcescens</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococci faecalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>(methicillineresistent - MRSA)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus mitis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus sanguis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Chryseobacterium indologenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Burkholderia cepacia</em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic bacteria</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Propionibacterium acnes</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.</p><p>&nbsp;</p><p><u>PK/PD relationship</u></p><p>A specific PK/PD relationship has not been established for TOBREX. Published in vitro and in vivo studies have shown that tobramycin features a prolonged post-antibiotic effect, which effectively suppresses bacterial growth despite low serum concentrations.&nbsp;</p><p>Systemic administration studies have reported higher maximum concentrations with once daily compared to multiple daily dosing regimens. However, the weight of current evidence suggests that once daily systemic dosing is equally as efficacious as multiple-daily dosing. Tobramycin exhibits a concentration-dependent antimicrobial kill and greater efficacy with increasing levels of antibiotic above the MIC or minimum bactericidal concentration (MBC).</p><p>&nbsp;</p><p><u>Data from clinical studies&nbsp;&nbsp; </u></p><p>Pharmacodynamic clinical trials of cumulative safety data from clinical studies are presented in section 4.8.</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>No overall clinical differences in safety or efficacy have been observed between the elderly and other adult populations.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Over 600 paediatric patients were enrolled in 10 clinical studies with tobramycin eye drops or eye ointment for the treatment of bacterial conjunctivitis, blepharitis, or blepharoconjunctivitis. These patients ranged in age from 1 year to 18 years. Overall, the safety profile in paediatric patients was comparable to that of adult patients. For children younger than age 1, no recommendation on a posology can be made<br />due to a lack of data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Tobramycin is poorly absorbed across rabbit cornea and conjunctiva and minimal amounts are absorbed into the eye after topical administration of tobramycin.</p><p>Additionally, systemic absorption of tobramycin is poor clinically after topical ocular administration of tobramycin products with similar concentration to TOBREX (0.3%).</p><p>The high concentration of tobramycin in TOBREX delivers tobramycin at the site of infection (ocular surface) at a concentration generally much higher than the MIC of the most resistant isolates (MICs &gt; 64 mg/ml; tobramycin concentration in human eye after a single dose of TOBREX is 848 &plusmn; 674 mg/ml, 1 minute after dosing).</p><p>&nbsp;</p><p>Tobramycin concentration in healthy human tears remains over MIC<sub>90</sub> (16 mg/ml as described for ocular isolates) at least up to 44 minutes post dosing of a treatment with TOBREX.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution is 0.26 l/kg in man. Human plasma protein binding of tobramycin is low at less than 10%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Tobramycin is excreted in the urine primarily as unchanged drug.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Tobramycin is excreted rapidly and extensively in the urine via glomerular filtration, primarily as unchanged drug. The plasma half-life is approximately two hours. &nbsp;The reported systemic clearance in adult subjects with normal renal function ranged from of 0.05 &ndash; 0.1 L/hr/kg and decreased with decreased renal function.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>Ocular or systemic absorption with increasing dosing concentrations after topical ocular administration has not been tested. Therefore, the linearity of exposure with ocular dose could not be established.</p><p>&nbsp;</p><p><u>Use in hepatic and renal impairment</u></p><p>TOBREX eye drops and eye ointment have not been studied in these patient populations. However, due to low systemic absorption of tobramycin after topical administration of this product, dose adjustment is not necessary.</p><p>&nbsp;</p><p><u>Use in paediatrics</u></p><p>TOBREX may be used in paediatric patients (1 year of age and older) at the same dose as in adults. However, limited information is available in paediatric patients younger than 1 year of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tobramycin is very poorly absorbed from the gastrointestinal tract. High parenterally administered doses of tobramycin have been reported to cause renal toxicity in rats and dogs, and ototoxicity in cats.</p><p>&nbsp;</p><p>Preclinical studies have shown high systemic doses of tobramycin were administered using the intra-peritoneal (IP) route at 30 and 60 mg/kg to rats during periods of major organogenesis; which caused increases in glomerular density and the loss of cortical area within the kidney in the fetuses and in newborn rats. Similarly in other laboratory animals, aminoglycoside antibiotics are considered to be ototoxic. Prolonged systemic treatment of tobramycin in cats administered using the subcutaneous route at 20, 40 and 80 mg/kg/day for 30 weeks resulted in dose-dependent degeneration of hair cells and supporting sensory structures in the ear.&nbsp; However, the human ear is now perceived as being anatomically more protected and thereby, less vulnerable to aminoglycoside-induced injury than with the animal models.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>TOBREX eye ointment:</u></p><ol><li>Anhydrous chlorobutanol</li><li>Liquid paraffine</li><li>Vaseline</li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific incompatibility studies have been undertaken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
Discard 4 weeks after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TOBREX eye ointment is supplied in a 3.5 g aluminium tube with a screw cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/09/2019 By Belgian health authorities
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>